Anti-Microbial Resistance

 

 

The impact of rising resistance has made the development of effective vaccines against otherwise lethal bacterial infections paramount. 

While efforts towards developing new and effective antibiotics will take a number of years, vaccines could provide the immunity that could help us in catching up with the arms race.

For the third year running, we’re dedicating an entire day to AMR sessions, planned together with Dr Jan T Poolman, Head Bacterial Vaccine Discovery and Early Development at Janssen and Dr Kathrin Jansen, VP, CSO Bacterial Vaccines at Pfizer to cover the role of vaccines, public awareness and industry in preventing a further AMR crisis.

Who Sponsors?

 

 

This is a prime opportunity for specialists in oncology from:

  • CROs and Pre-Clinical CROs 
  • Drug Discovery, Collaborative Data, Registries, Translational Science and Academia/Research Institutes 
  • Consultants (Reg/Mkt Access/Comm) 
  • Biopharma, Biotech, Biofilm 
  • Molecular Diagnostics, In-Vitro Diagnostics, Point-of-Care Diagnostics, Antimicrobial testing labs
  • Bioinformatics, bioanalytics, biodata tech, biosimulation
  • Stewardship 
  • CMOs, Equipment, consumables

Who Attends

 

 

  • Pharma 
  • Biotech
  • Government
  • Academia & Research Institutions 
  • Public Agencies & Associations 

Job Titles

 

 

  • CEO
  • Chief/VP of R&D
  • Head, SVP, VP, Director of: Infectious Diseases 
  • President, Global Development
  • VP, Clinical Development
  • Chief Medical Officer
  • VP of Microbiology
  • VP of Antibacterial, Antibiotic
  • Principal Investigators
  • Scientists 
  • Strategic Alliance
  • Alliance/Partnership Development
  • VP of Microbiology
 

 

2018 AGENDA

 

Anti-Microbial Resistance, Tuesday 30 October 2018

Opening Plenary Session

Dr Martin Friede
09:40

Short morning break followed by session tracks

Anti-Microbial Resistance

Fighting Anti-Microbial Resistance

Professor Mark Wilcox
Anti-Microbial Resistance
10:15

What can we do to manage AMR? MRSA, C.diff and E.coli control efforts including Abx practices

Dr Elizabeth Klemm
Anti-Microbial Resistance
10:45

Opportunities and challenges for developing vaccines to tackle AMR

11:05

Morning Networking Break

Prof Marc Bonten
Anti-Microbial Resistance
12:05

Why and how the Netherlands maintain one of the lowest AMR rates? What bugs can be stopped by vaccines and which likely are more difficult

Dr Anthony Simon Lynch
Anti-Microbial Resistance
12:35

Phasing out broad spectrum antimicrobial use: issues, challenges and potential paths forward?

The current unnecessary use of broad-spectrum antibiotics results in both microbiome dysbiosis-related health issues and the emergence and spread of antibiotic-resistance traits – and therein set-up the anticipated role of pathogen-targeted antibiotics and antibacterial vaccines in limiting the future emergence and spread of AMR
Dr Hanneke Schuitemaker
Anti-Microbial Resistance
13:05

Viral vaccines RSV & influenza: The mis-use of Abx in respiratory infections

13:35

Networking Lunch & Poster Session

Prof Ron Dagan
Anti-Microbial Resistance
15:05

Reduction of otitis by pneumococcal conjugates

Prof Mark Hatherill
Anti-Microbial Resistance
15:35

TB, A global problem: One of the biggest bacterial disease burden

Dr Annaliesa Anderson
Anti-Microbial Resistance
17:05

Progress towards developing a prophylactic Vaccine for the prevention of Clostridium difficile infections

Chair closing remarks of day one followed by Drinks Reception

last published: 22/Oct/18 10:55

Anti-Microbial Resistance, Wednesday 31 October 2018

10:40

Morning Networking Break

12:50

Afternoon Networking Lunch

AFTERNOON PLENARY TALKS

Dr Giovanna Zanoni
Dr Helen Bright
14:50

Flumist vaccine effectiveness – It’s return and the real story

  • Questions over the effectiveness of the live attenuated vaccine
  • Why it lost its recommendation
  • The journey, investigation and trial data to rectify this
Dr Rino Rappuoli
15:15

Closing plenary: The future of vaccinology: Incorporating bioinformatics, omics and structural vaccinology into vaccine design

  • The Human Immunologic Setpoint: Baseline immune status predicts vaccine response
  • A bottleneck for all, the ability to manage and analyze in an integrative with all the data that is generated
  • interpreting everything into something meaningful

Chair’s closing remarks and close of congress

last published: 22/Oct/18 10:55

Sign Up for Event Updates